Dermatology Online Journal · 2019 · 31 citations · 6 references
MedicineDermatologyOncologyCancer PharmacologyCutaneous OncologyHypersensitivityCutaneous Metastatic DiseaseDermal ToxicityDrug-induced Skin ReactionsImmunopathology Of SkinInterface DermatitisSkin TumorsAntibody-drug Conjugate AntibodiesAntibody-drug Conjugate TherapyCutaneous Metastatic TumorsDermatologic Adverse EventsDrug-induced Interface DermatitisMetastatic Urothelial Carcinoma ImmunotherapyTreatment With Topical CorticosteroidsVacuolar Dermatitis
Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 and is being studied in the treatment of various epithelial carcinomas including urothelial carcinoma; early data suggests efficacy and tolerability. Rash has been described as an adverse event associated with treatment with enfortumab vedotin, but has not been characterized to date. We report a patient with metastatic urothelial carcinoma treated with enfortumab vedotin who developed erythematous, scaly papules and plaques on his torso and extremities with corresponding histologic features of vacuolar interface dermatitis and maturation disarray of keratinocytes. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.
6
Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles et al. · The Lancet Oncology · 2015 · 335 citations
Pharmacy, Immunology, Oncology +16
R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2012 · 209 citations
Medicine, Oncology, Pharmacology +17
Denise A. Yardley, Robert Weaver, Michelle Melisko et al. · Journal of Clinical Oncology · 2015 · 189 citations · Full text
Medicine, Oncology, Pharmacology +17